Navigation Links
Jazz Pharmaceuticals Completes $7 Million Private Placement
Date:7/7/2009

PALO ALTO, Calif., July 7, 2009 /PRNewswire-FirstCall/ -- Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) today announced the signing and closing of a private placement of an aggregate of 1,895,734 units, comprised of an aggregate of 1,895,734 shares of common stock and warrants to purchase up to 947,867 additional shares of common stock for aggregate gross proceeds of approximately $7 million. The per unit purchase price for a share of common stock and a warrant to purchase 0.50 of a share of common stock was $3.6925. The warrants have an exercise price of $4.00 per share and are exercisable for seven years.

The gross proceeds of the private placement were $7.0 million, and the company intends to use the proceeds for general corporate purposes. The units were purchased by funds affiliated with Longitude Capital. In connection with the transaction, Patrick Enright, a Managing Director of Longitude Capital, joined Jazz Pharmaceuticals' Board of Directors.

The securities offered and sold by Jazz Pharmaceuticals in this private placement have not been registered under the Securities Act of 1933, as amended (the "Securities Act"), or state securities laws and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission ("SEC") or an applicable exemption from registration requirements. Jazz Pharmaceuticals has agreed to file a registration statement with the SEC covering resale of the shares of common stock and the shares of common stock issuable upon exercise of the warrants issued in the private placement.

About Jazz Pharmaceuticals, Inc.

Jazz Pharmaceuticals is a specialty pharmaceutical company that identifies, develops and commercializes innovative treatments for important, underserved markets in neurology and psychiatry. For further information plea
'/>"/>

SOURCE Jazz Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... (PRWEB) December 24, 2014 Risperdal lawsuit ... a mass tort litigation currently underway in Pennsylvania’s Philadelphia ... As of December 24, 2014, court documents indicate that ... behalf of individuals who developed gynecomastia (male breast growth) ... from the Court indicates that this represents an increase ...
(Date:12/24/2014)... Dr. Vu Ho, a Dallas based facial ... and med-spa with the addition of new Silk Peel ... treatments and services. , “Silk Peel is a procedure ... Ho. “As a result it can address issues like ... discolorations or blemishes.” , Similar to microdermabrasion, Silk ...
(Date:12/24/2014)... December 25, 2014 Today, UWDress.com, the famous ... sleeve wedding gowns, and launched a site-wide wedding gown promotion. ... sleeve wedding gowns in a more unexpected way, the collection ... are popular in the global market, and they are available ... UWDress.com are offered at discounted prices, up to 75% off; ...
(Date:12/24/2014)... Dallas, TX (PRWEB) December 25, 2014 ... Analysis to 2023” focuses on the current treatment landscape, ... colorectal cancer market. Stivarga is a drug which is ... This drug is orally administered and is also prescribed ... The drug which is FDA approved is a multi-kinase ...
(Date:12/24/2014)... (PRWEB) December 25, 2014 BambooIndustry.com a ... for many years. Today, the company announces its ... a special offer on these new products. , Bamboo ... renewable bamboo. The multiple layer bamboo panel board features ... both strong and emissions free. The bamboo panel consists ...
Breaking Medicine News(10 mins):Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 4Health News:Dr. Vu Ho Expands Facial Plastic Surgery Practice to Include New Skin Care Treatment 2Health News:Buy Cheap Long Sleeve Wedding Gowns At UWDress.com 2Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Bamboo Flooring Company Bambooindustry.com Introduces Its Multiple Layer Bamboo Panel Board Collection 2
... experts say, but safety concerns linger, , WEDNESDAY, Jan. ... oral, rather than injected -- may soon be available to ... online Jan. 20 in the New England Journal of ... cladribine -- reduce relapse rates in people with relapsing-remitting multiple ...
... Implications of Federal Medicare Cuts Require Careful Scrutiny and Consideration ... AUSTIN, Texas , Jan. 20 The ... Graves , today expressed concern about the growing cumulative pressure ... and protect Texas, most vulnerable nursing home residents. ...
... ... significantly higher risk of relapse attacks in patients with multiple sclerosis (MS) who develop the ... San Francisco. , ... 20, 2010 -- Low vitamin D blood levels are associated with a significantly higher ...
... ... market of medical silicone components. , ... Chicago, IL (PRWEB) January 20, 2010 -- Chicago-based medical silicone component manufacturer ... to market faster. , , , , ,FMI’s Rapid Development Program (RDP) is ...
... to Develop and Oversee Marketing and Strategic Partnership Initiatives ... WASHINGTON , Jan. 20 The Patient Advocate ... arbitration services to tens of thousands of patients every year ... of financial obstacles or insurance denials -- announced today the ...
... , ... to Haiti , Craig Juntunen , founder of Chances for Children, ... assist in a fresh renewal of the devastated nation of Haiti , ... Hole residents Lynn and Foster Friess augmented by a subsequent ...
Cached Medicine News:Health News:First Oral Medications For MS Show Promise 2Health News:First Oral Medications For MS Show Promise 3Health News:Texas Health Care Association: Meeting Texas Seniors' Ongoing Care Needs Threatened by Looming State, Federal Funding Threats 2Health News:Low Vitamin D Levels are Associated With Greater Risk of Relapse in Childhood-Onset Multiple Sclerosis 2Health News:Low Vitamin D Levels are Associated With Greater Risk of Relapse in Childhood-Onset Multiple Sclerosis 3Health News:Low Vitamin D Levels are Associated With Greater Risk of Relapse in Childhood-Onset Multiple Sclerosis 4Health News:FMI Introduces Rapid Development Program for Medical Silicone Components 2Health News:Patient Advocate Foundation Welcomes Former NASCAR Team Executive as New Executive Vice President of National Partnerships 2Health News:Patient Advocate Foundation Welcomes Former NASCAR Team Executive as New Executive Vice President of National Partnerships 3Health News:Chances for Children Launches 'Haiti Renewal Fund' With $2 Million From Foster Friess 2Health News:Chances for Children Launches 'Haiti Renewal Fund' With $2 Million From Foster Friess 3Health News:Chances for Children Launches 'Haiti Renewal Fund' With $2 Million From Foster Friess 4
(Date:12/24/2014)... CHAPEL HILL, N.C. , Dec. 23, 2014 /PRNewswire/ ... marketplace success. As the key link between the medical ... will grow even more in the coming years as ... relationships. According to research by benchmarking ... and MSLs can gain an important edge is by ...
(Date:12/22/2014)... , Dec. 22, 2014 Apnea Sciences ( ... offices in Aliso Viejo , California.  ... to the tremendous growth and worldwide expansion, a new ... patented SnoreRx, the anti snore cure have exceeded our ... "We are now in 23 countries and will ...
(Date:12/22/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/hmlfbq/investment ) ... Analysis of the US Medical Device Sector " ... http://photos.prnewswire.com/prnh/20130307/600769 This analysis ... identifies the key trends and rationale for undertaking ... and acquisitions. The study will be ...
Breaking Medicine Technology:Role of Medical Science Liaisons Evolving in Medical Device Sector 2Investment Analysis of the US Medical Device Sector 2
... 10, 2012 uVera Diagnostics has introduced the CR3 Keyless ... screening specimen cup provides several state-of-the-art features not available ... "This is revolutionary to the drug testing industry," said Rick ... designed for ease of use for both genders. The unique ...
...  - Agreement allows development for potential treatment of ... SHPGY ), the global specialty biopharmaceutical company, ... develop and market Resolor ® (prucalopride) in the ... N.V.  Terms of the agreement have not been disclosed. ...
Cached Medicine Technology:uVera Diagnostics Offers New Drug Screening Product 2Shire Acquires US Rights to Resolor(R) (prucalopride) 2Shire Acquires US Rights to Resolor(R) (prucalopride) 3Shire Acquires US Rights to Resolor(R) (prucalopride) 4
... the first intra-operative fluorescent imaging system ... the location of the coronary arteries ... coronary artery bypass procedures. ,The patented ... to view, record, replay, print, and ...
... When myocardial infarction is ... TROPT sensitive rapid assay allows ... marker troponin T from a ... qualitative result is available within ...
The Polygraf ID multi-parametric recorder works with POLYGRAM NET analysis software to create a unique interface that combines web-style navigation, graphical presentation and intuitive design to del...
... The White Sun light source offers the industry ... Kelvin color temperature at a lower price. A ... White Sun to be used with Olympus, Storz, ... light output LED and re-settable bulb timer. The ...
Medicine Products: